Fate Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
June 01 2018 - 4:01PM
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage
biopharmaceutical company dedicated to the development of
programmed cellular immunotherapies for cancer and immune
disorders, announced today that Scott Wolchko, President and Chief
Executive Officer, will present at the Jefferies 2018 Global
Healthcare Conference in New York on Thursday, June 7, 2018 at 9:30
a.m. ET.
A live webcast of the presentation will be
available through the investor relations section of the Company's
website at www.fatetherapeutics.com. Following the live webcast, an
archived replay will be available on the Company's website.
About Fate Therapeutics, Inc. Fate
Therapeutics is a clinical-stage biopharmaceutical company
dedicated to the development of first-in-class cellular
immunotherapies for cancer and immune disorders. The Company is
pioneering the development of off-the-shelf cell products using its
proprietary induced pluripotent stem cell (iPSC) product platform.
The Company’s immuno-oncology pipeline is comprised of FATE-NK100,
a donor-derived natural killer (NK) cell cancer immunotherapy that
is currently being evaluated in three Phase 1 clinical trials, as
well as iPSC-derived NK cell and T-cell immunotherapies, with a
focus on developing augmented cell products intended to synergize
with checkpoint inhibitor and monoclonal antibody therapies and to
target tumor-specific antigens. The Company’s immuno-regulatory
pipeline includes ProTmune™, a next-generation donor cell graft
that is currently being evaluated in a Phase 2 clinical trial for
the prevention of graft-versus-host disease, and a myeloid-derived
suppressor cell immunotherapy for promoting immune tolerance in
patients with immune disorders. Fate Therapeutics is
headquartered in San Diego, CA. For more information,
please visit www.fatetherapeutics.com.
Contact: Christina Tartaglia Stern
Investor Relations, Inc. 212.362.1200 christina@sternir.com
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Sep 2023 to Sep 2024